Loading…
Mereo BioPharma Group plc is projected to decline to $0.3209 by 2027, a -2% move from its current price of $0.3287. MREO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.3101 | $0.3291 | $0.3492 | +0.11% |
| May 30 | $0.3029 | $0.3295 | $0.3583 | +0.23% |
| May 31 | $0.2976 | $0.3298 | $0.3656 | +0.35% |
| Jun 1 | $0.2932 | $0.3302 | $0.3719 | +0.46% |
| Jun 2 | $0.2895 | $0.3306 | $0.3775 | +0.58% |
| Jun 3 | $0.2862 | $0.331 | $0.3828 | +0.69% |
| Jun 4 | $0.2832 | $0.3314 | $0.3877 | +0.81% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2832 | $0.3314 | $0.3877 | +0.81% |
| Week 2 | $0.2675 | $0.334 | $0.4171 | +1.62% |
| Week 3 | $0.2565 | $0.3367 | $0.4421 | +2.44% |
| Week 4 | $0.2479 | $0.3394 | $0.4648 | +3.27% |
| Week 5 | $0.2408 | $0.3422 | $0.4862 | +4.10% |
| Week 6 | $0.2347 | $0.3449 | $0.5069 | +4.94% |
| Week 7 | $0.2295 | $0.3477 | $0.527 | +5.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Mereo BioPharma Group plc is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2; Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Mereo BioPharma Group plc (MREO) is a biopharmaceutical company focused on therapies for rare diseases, with a portfolio spanning antibodies, small molecules and inhibitors. The stock is currently priced at $0.3287 and has a market cap of $52.47M, ranking 4519 by market capitalization. The price outlook is provided year by year, showing a path from the current level toward higher estimates by 2050, with a mix of neutral and bullish sentiment across years.
The forecast implies limited upside in the near term but substantial long-term potential, contingent on clinical progress and regulatory outcomes.
A major floor 39.3% below — a decisive break under it would weaken the trend.
The nearest floor, 27.9% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 94.7% above — clearing it would confirm fresh momentum.
Key MREO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MREO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2992 | Buy | $0.3024 | Buy |
| MA 10 | $0.2719 | Buy | $0.2847 | Buy |
| MA 20 | $0.2653 | Buy | $0.2797 | Buy |
| MA 50 | $0.3025 | Buy | $0.3314 | Sell |
| MA 100 | $0.3753 | Sell | $0.5461 | Sell |
| MA 200 | $1.11 | Sell | $1.01 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.08 | Neutral |
| Stoch RSI (14) | 95.27 | Sell |
| CCI (20) | 194.29 | Buy |
| Williams %R (14) | -5.15 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 31.60 | Buy |
| Bollinger %B (20,2) | 1.08 | Sell |
| Stochastic %K (14) | 94.85 | Sell |
| TRIX (15) | -0.73 | Sell |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 76.47 | Sell |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 0.33 | Buy |
| ADX (14) | 24.92 | Buy |
| ATR (14) | 0.01 | Info |
The 30-day technical picture shows a bullish sentiment, with RSI4 14 at 60. The 50-day simple moving average is $0.3025 and the 200-day simple moving average is $1.11, indicating the price currently sits above the 50-day average but well below the longer-term average.
Support is at $0.237 and resistance at $0.339, framing a modest near-term trading band. The 30-day price range spans from $0.2222 to $0.4862, highlighting a range-bound pattern with upside potential if resistance is broken.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.237 | $0.3287 | $0.4698 | 0% | Neutral | |
| $0.2309 | $0.3209 | $0.4825 | -2% | Neutral | |
| $0.2356 | $0.3474 | $0.5553 | +6% | Neutral | |
| $0.1829 | $0.2839 | $0.4759 | -14% | Neutral | |
| $0.2166 | $0.3523 | $0.6141 | +7% | Neutral | |
| $0.2886 | $0.4905 | $0.8846 | +49% | Bullish | |
| $0.2601 | $0.461 | $0.857 | +40% | Bullish | |
| $0.263 | $0.4853 | $0.927 | +48% | Bullish | |
| $0.2237 | $0.4294 | $0.8406 | +31% | Bullish | |
| $0.1799 | $0.3589 | $0.7188 | +9% | Neutral | |
| $0.2667 | $0.5926 | $1.30 | +80% | Bullish | |
| $0.5727 | $1.27 | $2.93 | +287% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.237 | $0.3287 | $0.3911 | +0.00% |
| June 2026 | $0.2925 | $0.3508 | $0.436 | +6.74% |
| July 2026 | $0.2993 | $0.365 | $0.4652 | +4.04% |
| August 2026 | $0.2842 | $0.3513 | $0.4565 | -3.75% |
| September 2026 | $0.2819 | $0.3523 | $0.465 | +0.29% |
| October 2026 | $0.2925 | $0.3693 | $0.4942 | +4.82% |
| November 2026 | $0.2829 | $0.3605 | $0.4883 | -2.39% |
| December 2026 | $0.2668 | $0.3429 | $0.4698 | -4.88% |
Click any year to see its month-by-month MREO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MREO is projected to trade between $0.237 and $0.4698, averaging $0.3287 — a potential gain of 0% from today's $0.3287. Price action looks broadly range-bound.
Mereo BioPharma Group plc's 2027 outlook centres on $0.3209, within a $0.2309 to $0.4825 range. That is -2% versus the projected 2026 average. That marks a -2% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, MREO could reach as high as $0.5553, with a base case around $0.3474 and support toward $0.2356 — roughly +6% from $0.3287. Price action looks broadly range-bound.
Expect MREO to range from $0.1829 to $0.4759 through 2029. The $0.2839 average target implies a -14% move from current prices. That is -18% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The MREO price prediction for 2030 points to an average of $0.3523 (low $0.2166, high $0.6141) — a potential gain of +7% on today's $0.3287. Price action looks broadly range-bound.
In 2031, MREO is projected to trade between $0.2886 and $0.8846, averaging $0.4905 — a potential gain of +49% from today's $0.3287. That is up +39% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Mereo BioPharma Group plc's 2032 outlook centres on $0.461, within a $0.2601 to $0.857 range. That is -6% versus the projected 2031 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2033, MREO could reach as high as $0.927, with a base case around $0.4853 and support toward $0.263 — roughly +48% from $0.3287. Buyers look set to stay in control over this stretch.
Expect MREO to range from $0.2237 to $0.8406 through 2034. The $0.4294 average target implies a +31% move from current prices. That is -12% versus the projected 2033 average. Momentum favours further upside here.
The MREO price prediction for 2035 points to an average of $0.3589 (low $0.1799, high $0.7188) — a potential gain of +9% on today's $0.3287. A consolidation phase looks the most probable path here.
In 2040, MREO is projected to trade between $0.2667 and $1.30, averaging $0.5926 — a potential gain of +80% from today's $0.3287. That is up +65% on the projected 2035 average. Momentum favours further upside here.
Mereo BioPharma Group plc's 2050 outlook centres on $1.27, within a $0.5727 to $2.93 range. That is up +115% on the projected 2040 average. That marks a +287% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MREO today (≈ 3,042.2878 MREO) could be worth
$3,871.55
+$2,871.55 (+287%) by 2050 · US Dollar
Based on the average projected MREO price of $1.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MREOwould be worth at today's price.
$1,000 invested in MREO on May 27, 2025 (≈ 458.715582 MREO) would be worth
$150.78
-$849.22 (-84.9%) today · 0.15× · US Dollar
Based on a MREO entry price of $2.18 vs. today's $0.3287.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.283 | $1,161.48 | +16.1% |
| 1 month ago | $0.28 | $1,173.93 | +17.4% |
| 3 months ago | $0.386 | $851.55 | -14.8% |
| 6 months ago | $1.87 | $175.78 | -82.4% |
| 1 year ago | $2.18 | $150.78 | -84.9% |
| All time (5.0y) ago | $3.46 | $95 | -90.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MREO forecast.
Our base-case forecast reaches $0.66 around 2050.
Implied market cap at $0.66: $105.35M
The multi-year forecast presents an upward trajectory, with the 2030 average price at $0.3523 and a 7.2% ROI. The sequence continues with 2031 at an average of $0.4905 and a 49.2% ROI, then 2032 at $0.461, 2033 at $0.4853, and 2034 at $0.4294, followed by 2035 at $0.3589.
By 2040, the average forecast rises to $0.5926 with an 80.3% ROI. The 2050 outlook shows a strong rise to an average of $1.27 and a max of $2.93, supported by a 287.2% ROI and a bullish sentiment. These values are estimates and not guarantees, and actual results will depend on a range of clinical, regulatory, and market factors.
Tap a question to reveal the answer.
Avg $0.3523; min $0.2166; max $0.6141; ROI 7.2; sentiment NEUTRAL.
Forecasts show positive momentum later (2031 ROI 49.2; 2040 ROI 80.3; 2050 ROI 287.2) but there are years with negative or muted returns (e.g., 2027 ROI -2.4; 2029 ROI -13.6). The outlook is mixed and not guaranteed.
Yes, the max forecast includes $1.30 in 2040 and $2.93 in 2050.
Current price $0.3287; market cap $52.47M.
RSI14 is 60; sentiment is BULLISH. SMA50 is $0.3025 and SMA200 is $1.11. Support is $0.237 and resistance is $0.339. The 30-day range is $0.2222-$0.4862.
Mereo BioPharma Group plc Community Discussion
0Share your Mereo BioPharma Group plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.